A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 16 Apr 2025
At a glance
- Drugs TQC 3721 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 16 Apr 2025 last checked against ClinicalTrials.gov: US National Institutes of Health.
- 11 Apr 2025 Status changed from recruiting to completed.
- 23 Sep 2024 Status changed from not yet recruiting to recruiting.